CLDN18.2

Professor Shen Lin’s Team Tackles Gastric Cancer! CLDN18.2 Targeted ADC Drug IBI343 Phase I Study Tops Nature Medicine

by
Professor Shen Lin's Team Tackles Gastric Cancer! CLDN18.2 Targeted ADC Drug IBI343 Phase I Study Tops Nature Medicine

Professor Shen Lin’s team tackles gastric cancer! The CLDN18.2 targeted ADC drug IBI343 Phase I study tops Nature Medicine. Gastric cancer, as a “health killer” globally, is particularly rampant in East Asia. Data shows that in 2022, there were 358,700 new cases of gastric cancer in China, with 260,400 deaths, accounting for nearly 40% of … Read more

China’s Strong Voice | New Achievements in Anti-CLDN18.2 ADC, Latest Research Results of IBI343 Revealed

by
China's Strong Voice | New Achievements in Anti-CLDN18.2 ADC, Latest Research Results of IBI343 Revealed

Introduction Gastric cancer remains a significant public health challenge globally, ranking fifth in incidence and mortality among all cancer types. In recent years, targeted therapy and immunotherapy have greatly improved survival for patients with gastric cancer/gastroesophageal junction cancer (GC/GEJC). However, there are few meaningful therapeutic targets in the field of gastric cancer, and the benefits … Read more